PDS Biotechnology Corp reports results for the quarter ended December 31 - Earnings Summary
27/03/2025 13:31
PDS Biotechnology Corp PDSB.OQ reported a quarterly adjusted loss of 21 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of four analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -29 cents to -25 cents per share. Reported revenue was zero; analysts expected zero. PDS Biotechnology Corp's reported EPS for the quarter was a loss of 21 cents. The company reported a quarterly loss of $7.95 million. PDS Biotechnology Corp shares had fallen by 23.9% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 8.4% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for PDS Biotechnology Corp is $7.50 This summary was machine generated from LSEG data March 27 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.28 | -0.21 | Beat |
| Sep. 30 2024 | -0.28 | -0.29 | Missed |
| Jun. 30 2024 | -0.34 | -0.23 | Beat |
| Mar. 31 2024 | -0.37 | -0.30 | Beat |
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing